Main Menu

News and features

The ICR’s media team works to increase the profile of the organisation by showcasing the cutting-edge research carried out by our scientists and development initiatives. 

For more information you can always contact our media team, or visit our press release archive to view a list of our press releases. 

News

Risk of premature menopause after cancer treatment mapped 22
Aug
2014

Women treated for the cancer Hodgkin lymphoma will be able to better understand their risks of future infertility after researchers estimated their risk of premature menopause with different treatments. Find out more

Statement in response to rejection of abiraterone before chemotherapy in final draft guidance from NICE 14
Aug
2014

Our Interim Chief Executive, Professor Paul Workman, comments on today’s rejection of abiraterone before chemotherapy in final draft guidance from NICE. Find out more

Mutations in a gene essential for cell regulation cause kidney cancer in children 07
Aug
2014

Mutations in a gene that helps regulate when genes are switched on and off in cells have been found to cause rare cases of Wilms tumour, the most common kidney cancer occurring in children. Find out more

See all news articles

Features

Exploiting the cell cycle to improve radiotherapy outcomes 20
Aug
2014

One of the crucial signalling networks that often go awry in cancer are those that respond to DNA damage and regulate the cell cycle progression. But now researchers are turning this to their advantage, and are attacking cancer by targeting one of the very processes that drives it – a faulty DNA repair response. Find out more

Darwinian evolution: from dinosaurs to cancer drug resistance 15
Jul
2014

Birds evolving from dinosaurs, fish emerging from the sea, and hominids adopting an upright posture – all are iconic examples of evolution. On the surface they don’t have a great deal to do with cancer, but the process underlying them both — natural selection — is identical. Find out more

The story of abiraterone 11
May
2014

Abiraterone is one of the ICR’s biggest success stories: the first treatment shown to be effective in men with advanced prostate cancer. But it took almost 20-years of hard work to take the drug from an initial idea to the clinic, where it now transforms the lives of more than 25,000 patients every year. Find out more

See all feature articles
We use cookies to ensure that we give you the best experience on our website. By continuing to use this website, you are agreeing to our use of cookies on your device as described in our cookie policy. You can change your cookie settings at any time but parts of our site will not function correctly without them.